Cantor’s Elemer Piros now expects 52% in return potential for GWPH stock and sets a 100% probability of success for Epidiolex.
On back of yesterday’s positive briefing documents, Cowen’s Phil Nadeau roots for FDA approval.
GW Pharmaceuticals (NASDAQ:GWPH) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 11% upturn. …
The hedge fund firm founder is stepping into tech stock HMNY and biopharma stock GWPH; here’s how these Q4 moves measure up against the word on the Street.
If you’ve been waiting patiently on the sidelines for a pullback in GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), it’s here. The drug maker’s shares …
Shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) tumbled nearly 5% in after-hours trading Wednesday, after the drug maker announced negative results with GWP42006 in …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is aiming for an EMA marketing green light for Epidiolex, its lead cannabidiol or CBD product candidate, designed …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) investors will be smiling to hear the drug maker’s good news today: FDA acceptance for filing with Priority …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares tumble nearly 9% in Friday’s trading session, following the news that competitor Zogenix, Inc. (NASDAQ:ZGNX) achieved impressive results …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares were falling 2% yesterday after the biotech company handed over its third-fiscal quarter print for the year, …